retatrutide clinical trial dosage Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP Retatrutide for Weight Loss: 2026

Patient progress may reflect an individualized combination of medical evaluation, nutrition guidance, activity planning, behavioral support, ongoing monitoring, and clinically appropriate treatment

Mild to moderate diarrhea is generally not dangerous and often resolves within 8-12 weeks as your body adapts

Treatments Offered Compounded GLP-1 injections: semaglutide

The cardiovascular and renal outcomes of DPP4i have been summarized in Table 5

But Wegovy may increase the risk of pancreatitis, gallbladder disease, severe gastrointestinal side effects that may lead to dehydration or kidney injury, increased heart rate, and suicidal thoughts or behaviors

These products are intended for research purposes and exist in a regulatory gray area